SCHEMBL974951

SCHEMBL974951

CO[C@H]1O[C@H](COC(=O)c2ccccc2)[C@@H](OC(=O)c2ccccc2)[C@H](O[C@H]2O[C@H](COC(=O)c3ccccc3)[C@@H](OC(=O)c3ccccc3)[C@H](O[C@H]3O[C@H](COC(=O)c4ccccc4)[C@@H](OC(=O)c4ccccc4)[C@H](O)[C@@H]3OC(=O)c3ccccc3)[C@@H]2OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 0.48
LGALS3 P17931 3/20 0.46
LGALS9 O00182 2/20 0.46
LGALS1 P09382 2/20 0.46
LGALS7; LGALS7B P47929 2/20 0.46
USP2 O75604 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
ANTXR2 P58335 1/20 0.44
LGALS4 P56470 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN11 Q06124 1/20 0.43
F11 P03951 2/20 0.42
TMPRSS2 O15393 1/20 0.42
PDE5A O76074 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
HMGCR P04035 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974953 1.00 PTPN1 (0.48) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL977896 1.00 PTPN1 (0.48) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL977898 1.00 PTPN1 (0.48) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL976416 0.93 PTPN1 (0.48) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL16316511 0.92 PTPN1 (0.51) PTPN1USP2MEN1POLBKMT2A
SCHEMBL14440519 0.92 PTPN1 (0.50) PTPN1LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL24192988 0.91 ANTXR2 (0.53) PTPN1USP2MEN1POLBKMT2A
SCHEMBL14199422 0.91 TSHR (0.48) USP2MEN1POLBKMT2ACA1
SCHEMBL10700635 0.90 PTPN1 (0.57) PTPN1LGALS3USP2MEN1POLB
SCHEMBL11232105 0.90 PTPN1 (0.57) PTPN1LGALS3USP2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720889-B1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LTD (AU) 2014-11-26 EP disclosed
US-8173606-B2 Sulfated oligosaccharide derivatives PROGEN PHARMACEUTICALS LIMITED (AU) 2012-05-08 US disclosed
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LIMITED (AU) 2011-06-02 US disclosed
US-7875592-B2 inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease PROGEN PHARMACEUTICALS LIMITED (AU) 2011-01-25 US disclosed
US-20070185037-A1 Sulfated oligosaccharide derivatives PROGEN INDUSTRIES LIMITED (AU) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185037-A1 Sulfated oligosaccharide derivatives HPSE, APOB, LIPG PTPN1 612/4885LGALS3 116/4885LGALS9 146/4885
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES HPSE, APOB, LIPG PTPN1 612/4885LGALS3 116/4885LGALS9 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.